You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Scientists find new promising antibodies against novel coronavirus

Scientists have identified and further developed novel antibody fragments from llamas and alpacas that can be used against the SARS CoV-2 virus which causes COVID-19.


Press Trust of India  |  New Delhi 

Coronavirus, vaccine, covid, drugs, clinical trials

Scientists have identified and further developed novel antibody fragments from llamas and alpacas that can be used against the SARS CoV-2 virus which causes COVID-19.

These "nanobodies" identified by an international team led by the University of Bonn in Germany are smaller than classic antibodies.

They can penetrate the tissue better and can be produced in larger quantities.

The team also combined the nanobodies into potentially effective molecules attacking different parts of the virus simultaneously.

The approach, described in the journal Science, could prevent the pathogen from evading the active agent through mutations.

Antibodies are an important weapon in the immune system's defence against infections.

They bind to the surface structures of bacteria or viruses and prevent their replication.

One strategy in the fight against disease is therefore to produce effective antibodies in large quantities and inject them into the patients.

However, the immune system produces an almost infinite number of different antibodies, and they all recognise different target structures, the researchers said.

Only very few of them are for example capable of defeating the SARS coronavirus-2, they said.

"We first injected a surface protein of the into an alpaca and a llama," explained Florian Schmidt, from the University of Bonn's Institute of Innate Immunity.

"Their immune system then produces mainly antibodies directed against this virus. In addition to complex normal antibodies, llamas and alpacas also produce a simpler antibody variant that can serve as the basis for nanobodies," Schmidt said.

A few weeks later, the researchers took a blood sample from the animals, from which they extracted the genetic information of produced antibodies.

This "library" still contained millions of different construction plans.

Using a complex process, they extracted those that recognise an important structure on the surface of the coronavirus, the spike protein.

"Altogether we obtained dozens of nanobodies, which we then analysed further," said Paul-Albert Konig, from the University of Bonn and lead author of the study.

Four molecules actually proved to be effective against the pathogen in cell cultures.

"Using X-ray structures and electron microscopy analyses, we were furthermore able to show how they interact with the spike protein of the virus," Konig added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, January 13 2021. 17:30 IST